Clinical evaluation of tobramycin in urinary tract infections.

@article{Altucci1976ClinicalEO,
  title={Clinical evaluation of tobramycin in urinary tract infections.},
  author={Paolo Altucci and Gabriella Abbate and A Gattoni and V. Leonessa},
  journal={The Journal of infectious diseases},
  year={1976},
  volume={134 Suppl},
  pages={
          S139-41
        }
}
Twenty-one patients with urinary tract infections due to Pseudomonas and coli-form bacilli were treated with 80-120 mg of tobramycin per day in two daily doses. Of these patients, 14 (67%) were cured, one improved, three (14%) showed no improvement, and three (14%) showed a substitution of the original pathogen by another organism. Urine cultures demonstrated rapid sterilization in the cases in which patients responsed well, and long-term sterility persisted in at least 50% of the subjects. 
Clinical evaluation of tobramycin in respiratory and systemic infections in immunodepressed and normal patients.
TLDR
Combined treatment with tobramycin and beta-lactam antibiotics resulted in clinical and bacteriological improvement in 50% of systemic immunodepressed patients with sepsis and/or pneumonia.
Treatment of serious gram-negative infections with aztreonam.
TLDR
Eighty percent of infections were cured by both clinical and microbiological criteria and each of the other 26 infections showed clinical improvement and Eradication of the infecting organism was achieved in 89% of infections without adverse reaction or drug toxicity.
Aminoglycosides in urology.
TREATMENT OF INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA
  • R. Benn
  • Biology, Medicine
    The Medical journal of Australia
  • 1977
TLDR
Gentamicin and the more recently introduced toramycin have much greater activity against this difficult orgamsm than their predecessors, and the initial in-vitro studies of the activity suggested that the minimal inhibitory concentration (MIC) was less than I J..lgjml, a concentration which could be readily achieved in plasma with the usual doses.
Tobramycin: an overview.
  • H. Neu
  • Biology
    The Journal of infectious diseases
  • 1976
TLDR
Tobinycin, one of the newest aminoglycoside agents, is the subject of this review and much of the material presented herein will be concerned with a comparison of tobramycin and other am inoglycosides, since only in this context can one determine the proper role for this agent.
Morphological and structural responsies of Fusobacterium nucleatum to fosfomycin
TLDR
It is confirmed that the Fusobacterium nucteatum contains non-volatile substance which can be passed off as polypeptide-like substance by the H2O2 bacterium.

References

SHOWING 1-6 OF 6 REFERENCES
Clinical and laboratory studies with tobramycin.
TLDR
31 patients suffering from infections caused by gram-negative organisms, including 18 due to Ps.
Tobramycin: bacteriological evaluation
TLDR
Of particular interest are the susceptibilities of strains of Pseudomonas aeruginosa to lower concentrations of tobramycin than to gentamicin, and the susceptibility of some “gentamicin-resistant‘’ strains of P. aerug inosa to tobramYcin.
The in-vitro activity of tobramycin compared with that of other aminoglycosides
TLDR
Sensitive strains of this species were shown to contain a small minority of cells resistant to these antibiotics, the presence of which is believed to account for the marked bactericidal synergy which was demonstrated between tobramycin and carbenicillin.
Tobramycin therapy in renal failure.